Vet Derm Clinical Update: Concomitant use of cyclosporine and oclacitinib (Apoquel)
Two groups of eight study beagles were used to determine the oral dose tolerance of short term concomitant use of oclacitinib and cyclosporine. One group was given only oclacitinib for 3 weeks and the other group both oclacitinib (0.4 - 0.6 mg/kg) and cyclosporine (5 mg/kg) for 3 weeks. Hematology, chemistry, coagulation and any adverse effects were recorded. A variety of gastrointestinal disturbances were noted in both groups, none of which were significant. ALT was significantly lower and BUN higher in the oclacitinib/cyclosporine group. There were no other clinically significant results associated with laboratory testing. Due to the prolonged onset of efficacy of cyclosporine alone, this study shows that prescribing concomitant oclacitinib is an alternative to corticosteroids during this lag phase. This may be helpful for situations where oclacitinib is available in small quantities or situations where the use of cyclosporine is clinically indicated over oclacitinib.
A. Panteri, et al. Repeated oral dose tolerance in dogs treated concomitantly with ciclosporin and oclacitinib for three weeks. Veterinary Dermatology, 27:22-e7, (2016).
|